iBio to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Update on Monday, November 16 ,2020
05 nov. 2020 16h30 HE
|
iBio, Inc.
BRYAN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will...
iBio Announces Appointment of Randy J. Maddux as Chief Operating Officer
03 nov. 2020 07h30 HE
|
iBio, Inc.
BRYAN, Texas, Nov. 03, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the...
Accomplished Financial Executive, Gary Sender, Joins iBio’s Board of Directors
15 oct. 2020 16h05 HE
|
iBio, Inc.
- Adds More Than 25 Years of Financial Leadership in Pharma/Biotech to the Team - - To Chair iBio’s Audit Committee and be Appointed to the Board’s Compensation Committee - BRYAN, Texas, Oct. 15,...
iBio Announces Appointment of Dr. Alexandra Kropotova to Board of Directors
15 oct. 2020 07h30 HE
|
iBio, Inc.
- Senior Biopharm Executive with 20 Years of Immuno-Inflammatory Disease Therapeutic Experience - -To be Appointed to the Board’s New Science & Technology Committee - BRYAN, Texas, Oct. 15,...
iBio Announces Appointment of Dr. Linda Armstrong to Board of Directors
14 oct. 2020 16h05 HE
|
iBio, Inc.
- Accomplished Biopharm Exec with Years of Clinical Experience in Respiratory Diseases - - To be Appointed to the Board’s New Science & Technology Committee - BRYAN, Texas, Oct. 14, 2020 ...
iBio Announces Financial Results for Fiscal Year Ended June 30, 2020
13 oct. 2020 16h05 HE
|
iBio, Inc.
BRYAN, Texas, Oct. 13, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its...
iBio Regains Compliance with NYSE American Continued Listing Standards
05 oct. 2020 07h30 HE
|
iBio, Inc.
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that on...
iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System
02 oct. 2020 07h00 HE
|
iBio, Inc.
- Project Focused on Proteins used in the Production of Blood Cells - NEW YORK, Oct. 02, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotech innovator and...
iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201
09 sept. 2020 08h45 HE
|
iBio, Inc.
– IBIO-201 Produced Anti-Spike Neutralizing Antibodies in Pre-Clinical Studies – – iBio Plans to Continue Development of IBIO-200, its Virus-Like Particle Platform – NEW YORK, Sept. 09, 2020 ...
iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic
28 août 2020 07h15 HE
|
iBio, Inc.
NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology innovator and biologics contract manufacturing organization, today announced...